posted on 2018-07-17, 07:58authored byHolger G. Adelmann
Pharmaceutical Research and Development (R&D) is a 'knowledge intensive'
business, requiring frequent and comprehensive knowledge transactions. One
necessary class of knowledge transactions concerns the constant evaluation of
incoming data from experiments, discussion of the data amongst scientists and
physicians and the ability to make informed operational and strategic decisions
amidst some uncertainty, particularly in the early phase of development. Because
of these uncertainties, it is important to constantly review decisions to verify their
validity as a drug development project moves on. As the decision-making is
inextricably bound to appropriate risk awareness and risk management, the
consideration of options and appropriate scenario planning, the application of
past experience to present information should help provide a balanced
assessment of risks prior to decision making. Experienced employees often
immediately apply what they remember of their past experience to present
problems. This past experience, together with the ability to abstract from past
solutions in order to be able to apply them to new problems may be the key to
robust sustainable decisions.
The author's research has used a combination of pilot studies, brainstorming
sessions, review meetings and surveys combined with actual working practice in
an iterative manner, which has been proven useful to address the specific aims
and objectives for the development, implementation and testing of a decision
support framework for clinical drug development called EPISTEME. All the aims
and objectives set at the outset of this research have been achieved.
AstraZeneca top management has also recently used the EPISTEME decision
support framework successfully to assess the impact of restructuring scenarios.
This and the endorsement and adoption of the final information model and
decision support framework by the AstraZeneca company, means that this
research project was successful, and can now provide the basis for many further
research projects on related topics at AstraZeneca and elsewhere.
This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/
Publication date
2008
Notes
A Doctoral Thesis. Submitted in partial fulfilment of the requirements for the award of Doctor of Philosophy at Loughborough University.